(Alliance News) - AstraZeneca PLC on Tuesday said it has entered into a deal to license a lung cancer therapy, in a deal worth up to USD1.5 billion. Read More
(Alliance News) - BP flags lower second-quarter production but expects stronger oil price realisations, while AstraZeneca agrees a lung cancer licensing deal with Dizal Pharmaceutical worth up to USD1.5 billion. Read More
(Alliance News) - GSK reports positive Jemperli trial data, while Plus500 posts record first-half revenue. Elsewhere, Heathrow's first-half passenger traffic edged higher despite a June decline caused by weaker Middle East travel. Read More
(Alliance News) - The FTSE 100 closed higher on Friday in calmer trading, boosted by double-digit gains from telecommunications firm Vodafone. Read More
(Alliance News) - Heavy falls in AstraZeneca saw London's FTSE 100 underperform European peers, while investors continue to weigh developments in the Middle East. Read More
(Alliance News) - Stock prices in London were mixed at midday on Thursday, with the FTSE 100 underperforming its European peers as a sharp fall in AstraZeneca outweighed gains elsewhere, while investors continued to monitor developments in the Middle East. Read More
(Alliance News) - Stock prices in London opened lower on Thursday, with the FTSE 100 lagging behind its European peers as a sharp fall in AstraZeneca overshadowed gains elsewhere in the market. Read More
(Alliance News) - AstraZeneca PLC on Thursday said Wainua, a cardiovascular drug that it is developing in partnership with Ionis Pharmaceuticals Inc, did not meet its primary endpoint in a phase III trial. Read More
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd are progressing towards a deal which could bring access to breast cancer drug Enhertu for some patients in England and Wales, Bloomberg reported on Wednesday. Read More
(Alliance News) - The FTSE 100 gave back early gains on Monday as falls in gold miners and AstraZeneca, plus soft construction figures, dampened early enthusiasm. Read More
(Alliance News) - European stocks soared on Thursday as weaker than expected US jobs figures dampened market worries of a near-term interest rate hike across the pond. Read More
(Alliance News) - Hutchmed China Ltd on Thursday announced regulatory approval for savolitinib, brand name 'ORPATHYS', for a form of gastric cancer with "a very poor prognosis". Read More
